lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-30 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Communist ideologies and ideas have acquired a new meaning since the Russian Revolution, as they became equivalent to the ideas of Marxism–Leninism, namely the interpretation of Marxism by Vladimir Lenin and his successors. Endorsing the final objective, namely the creation of a community-owning means of production and providing each of its participants with consumption "according to their needs", Marxism–Leninism puts forward the recognition of the class struggle as a dominating principle of a social change and development. In addition, workers (the proletariat) were to carry out the mission of reconstruction of the society. Conducting a socialist revolution led by what its proponents termed the "vanguard of the proletariat", defined as the communist party organised hierarchically through democratic centralism, was hailed to be a historical necessity by Marxist–Leninists. Moreover, the introduction of the proletarian dictatorship was advocated and classes deemed hostile were to be repressed. In the 1920s, it was first defined and formulated by Joseph Stalin based on his understanding of orthodox Marxism and Leninism. In 1934, Karl Radek suggested the formulation Marxism–Leninism–Stalinism in an article in Pravda to stress the importance of Stalin's leadership to the Marxist–Leninist ideology. Radek's suggestion failed to catch on, as Stalin as well as CPSU's ideologists preferred to continue the usage of Marxism–Leninism.
=== Poisoning === In 1982, the US Mint began minting pennies coated in copper but containing primarily zinc. Zinc pennies pose a risk of zinc toxicosis, which can be fatal. One reported case of chronic ingestion of 425 pennies (over 1 kg of zinc) resulted in death due to gastrointestinal bacterial and fungal sepsis. Another patient who ingested 12 grams of zinc showed only lethargy and ataxia (gross lack of coordination of muscle movements). Several other cases have been reported of humans suffering zinc intoxication by the ingestion of zinc coins. Pennies and other small coins are sometimes ingested by dogs, requiring veterinary removal of the foreign objects. The zinc content of some coins can cause zinc toxicity, commonly fatal in dogs through severe hemolytic anemia and liver or kidney damage; vomiting and diarrhea are possible symptoms. Zinc is highly toxic in parrots and poisoning can often be fatal. The consumption of fruit juices stored in galvanized cans has resulted in mass parrot poisonings with zinc.
=== Old model of coloration with four primaries === The ancient Greeks, under the influence of Aristotle, Democritus and Plato, considered that there were four basic colors that coincided with the four elements: earth (ochre), sky (blue), water (green) and fire (red), while black and white represented the light of day and the darkness of night. The four-color system is formed by the primaries yellow, green, blue and red, and was supported by Alberti in his "De Pictura" (1436), using the rectangle, rhombus, and color wheel to represent them.
Sources: en.wikipedia.org
== Television episodes == "Half-Life", Icons season 3, episode 17 (2004) "Half-Life", Odyssey 5 episode 17 (2002) "Half Life", La Femme Nikita season 2, episode 7 (1998) "Half Life", Logan's Run episode 6 (1977) "Half Life", Medical Investigation episode 17 (2005) "Half Life", New Tricks series 8, episode 9 (2011) "Half Life", Sea Patrol season 3, episode 7 (2009) "Half Life", SeaChange season 3, episode 13 (2000)
It requires the smallest sample size (typically ~200 ng) relative to other methods and has a high precision of 1~5 ‰. But this method is relatively slow and limited to the samples which can be applied in GC system.
The result was that on January 29, 1981, Adolfo Suárez made public on television his decision to resign from the presidency of the government and the party. He justified it with the enigmatic phrase: "I do not want the democratic system of coexistence to be, once again, a parenthesis in the life of Spain". Two days later Suárez gathered the "barons" of UCD who agreed to propose Leopoldo Calvo Sotelo as candidate for the presidency of the government. The political crisis that the country was going through worsened when it was known that ETA had assassinated José María Ryan, industrial engineer of the Lemóniz Nuclear Power Plant who had been kidnapped a few days before, and coincided with the death by torture in the Carabanchel Penitentiary Hospital of the presumed etarra José Ignacio Arregui. It also fueled the tension the signs of rejection that the kings received from representatives of Herri Batasuna when they visited the Casa De Juntas De Gernika together with the lehendakari Carlos Garaikoetxea.
Gokhan Okan, Can Baykal, Rifkiye Sarica. "Childhood bullous pemphigoid developed after the first vaccination." Journal of Dermatological Treatment Gokhan Okan, Pervin Vural. "Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID‐19 vaccine." Journal of Dermatological Treatment Gokhan Okan, Adile Merve Baki, Eda Yorulmaz, Semra Doğru‐Abbasoğlu, and Pervin Vural. "Serum Visfatin, Fetuin‐A, and Pentraxin 3 Levels in Patients with Psoriasis and Their Relation to Disease Severity". Journal of clinical laboratory analysis. Gokhan Okan, and Halil Ibrahim Canter. "Nicolau syndrome and perforator vessels: a new viewpoint for an old problem". Journal of Cutaneous and Ocular Toxicology. Gokhan Okan, and Can Baykal. "Nevoid hyperkeratosis of the nipple and areola: treatment with topical retinoic acid". Journal of the European Academy of Dermatology and Venereology. Gokhan Okan, Serpil Yaylaci, Onder Peker, Sabahattin Kaymakoglu, and Murat Saruc. "Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus". World Journal of gastroenterology. Can Baykal, Gökhan Okan, and Rifkiye Sarica. "Childhood bullous pemphigoid developed after the first vaccination". Journal of the American Academy of Dermatology. Gökhan Okan, "Atopik dermatitin baş boyun lokalizasyonlarında pityrosporum ovalenin rolü". ("The role of pityrosporum ovalen in head and neck localization of atopic dermatitis.") Gokhan Okan, Adile Merve Baki, Eda Yorulmaz, Semra Dogru-Abbasoglu, Pervin vural.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.